Biodesix, Inc.
BDSX
$0.2867
-$0.0132-4.40%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 74.46M | 71.32M | 65.56M | 60.90M | 54.85M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 74.46M | 71.32M | 65.56M | 60.90M | 54.85M |
| Cost of Revenue | 16.10M | 15.57M | 14.61M | 13.66M | 13.02M |
| Gross Profit | 58.36M | 55.75M | 50.96M | 47.25M | 41.83M |
| SG&A Expenses | 80.34M | 80.45M | 76.48M | 71.96M | 68.95M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 106.83M | 105.58M | 100.12M | 94.04M | 90.75M |
| Operating Income | -32.37M | -34.26M | -34.56M | -33.14M | -35.90M |
| Income Before Tax | -40.42M | -42.93M | -43.82M | -44.51M | -47.06M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -40.42 | -42.93 | -43.82 | -44.51 | -47.06 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -40.42M | -42.93M | -43.82M | -44.51M | -47.06M |
| EBIT | -32.37M | -34.26M | -34.56M | -33.14M | -35.90M |
| EBITDA | -26.58M | -28.49M | -29.26M | -28.55M | -31.94M |
| EPS Basic | -0.29 | -0.35 | -0.39 | -0.46 | -0.55 |
| Normalized Basic EPS | -0.18 | -0.22 | -0.24 | -0.29 | -0.34 |
| EPS Diluted | -0.29 | -0.35 | -0.39 | -0.46 | -0.55 |
| Normalized Diluted EPS | -0.18 | -0.22 | -0.24 | -0.29 | -0.34 |
| Average Basic Shares Outstanding | 566.61M | 517.23M | 462.96M | 396.37M | 347.71M |
| Average Diluted Shares Outstanding | 566.61M | 517.23M | 462.96M | 396.37M | 347.71M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |